Speciality Medicines Limited (BOM:544738)
India · Delayed Price · Currency is INR 166.00
+7.65 (4.83%)
At close: Sep 11, 2026
Speciality Medicines Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 752.85 | 582.71 | 275.25 | 232.41 | 404.44 |
Other Revenue | - | -0 | - | -0 | - |
| 752.85 | 582.71 | 275.25 | 232.41 | 404.44 | |
Revenue Growth | 29.20% | 111.71% | 18.43% | -42.54% | - |
Cost of Revenue | 541.41 | 421.91 | 182.09 | 163.01 | 350.57 |
Gross Profit | 211.44 | 160.81 | 93.16 | 69.4 | 53.87 |
Selling, General & Admin | 23.44 | 28.97 | 22.66 | 33.55 | 14.47 |
Other Operating Expenses | 51.19 | 40.31 | 17.9 | -0.24 | 16.65 |
Operating Expenses | 76.36 | 71.26 | 42.87 | 36.26 | 32.24 |
Operating Income | 135.09 | 89.55 | 50.29 | 33.14 | 21.64 |
Interest Expense | -7.25 | -3.69 | -6.05 | -3.42 | -0.21 |
Interest & Investment Income | 0 | 0 | - | - | 0.01 |
Currency Exchange Gain (Loss) | 8.24 | 2.07 | 1.32 | - | - |
Other Non Operating Income (Expenses) | -5.94 | -1.04 | -5.35 | -0.13 | -0.05 |
EBT Excluding Unusual Items | 130.14 | 86.9 | 40.22 | 29.6 | 21.39 |
Gain (Loss) on Sale of Investments | 0.05 | - | - | - | - |
Pretax Income | 130.19 | 86.9 | 40.22 | 29.6 | 21.39 |
Income Tax Expense | -0.14 | 14.94 | -0.3 | 7.59 | 6.59 |
Net Income | 130.33 | 71.96 | 40.51 | 22.01 | 14.79 |
Net Income to Common | 130.33 | 71.96 | 40.51 | 22.01 | 14.79 |
Net Income Growth | 81.11% | 77.62% | 84.08% | 48.77% | - |
Shares Outstanding (Basic) | 9 | 6 | 5 | 4 | 3 |
Shares Outstanding (Diluted) | 9 | 6 | 5 | 4 | 3 |
Shares Change | 35.91% | 25.77% | 42.99% | 17.75% | - |
EPS (Basic) | 14.90 | 11.18 | 7.92 | 6.15 | 4.87 |
EPS (Diluted) | 14.90 | 11.18 | 7.92 | 6.15 | 4.87 |
EPS Growth | 33.27% | 41.21% | 28.74% | 26.34% | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -12.89 | -70.39 | -48.25 | -37.69 | -12.87 |
Free Cash Flow Per Share | -1.47 | -10.94 | -9.43 | -10.53 | -4.23 |
Gross Margin | 28.09% | 27.60% | 33.85% | 29.86% | 13.32% |
Operating Margin | 17.94% | 15.37% | 18.27% | 14.26% | 5.35% |
Profit Margin | 17.31% | 12.35% | 14.72% | 9.47% | 3.66% |
Free Cash Flow Margin | -1.71% | -12.08% | -17.53% | -16.22% | -3.18% |
EBITDA | 136.7 | 91.44 | 52.61 | 36.09 | 22.75 |
EBITDA Margin | 18.16% | 15.69% | 19.11% | 15.53% | 5.63% |
D&A For EBITDA | 1.62 | 1.89 | 2.32 | 2.95 | 1.12 |
EBIT | 135.09 | 89.55 | 50.29 | 33.14 | 21.64 |
EBIT Margin | 17.94% | 15.37% | 18.27% | 14.26% | 5.35% |
Effective Tax Rate | - | 17.19% | - | 25.65% | 30.82% |
Revenue as Reported | 761.14 | 585.4 | 276.57 | 232.65 | 404.46 |
Advertising Expenses | - | - | 0.03 | 0.22 | 0.03 |